| Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma FE Davies, N Raje, T Hideshima, S Lentzsch, G Young, YT Tai, B Lin, ... Blood, The Journal of the American Society of Hematology 98 (1), 210-216, 2001 | 1242 | 2001 |
| A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib D Chauhan, L Catley, G Li, K Podar, T Hideshima, M Velankar, ... Cancer cell 8 (5), 407-419, 2005 | 855 | 2005 |
| Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 T Hideshima, C Mitsiades, M Akiyama, T Hayashi, D Chauhan, ... Blood, The Journal of the American Society of Hematology 101 (4), 1530-1534, 2003 | 763 | 2003 |
| Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications D Gupta, SP Treon, Y Shima, T Hideshima, K Podar, YT Tai, B Lin, ... Leukemia 15 (12), 1950-1961, 2001 | 744 | 2001 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 661 | 2019 |
| Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration K Podar, YT Tai, FE Davies, S Lentzsch, M Sattler, T Hideshima, BK Lin, ... Blood, The Journal of the American Society of Hematology 98 (2), 428-435, 2001 | 590 | 2001 |
| Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu YT Tai, M Dillon, W Song, M Leiba, XF Li, P Burger, AI Lee, K Podar, ... Blood, The Journal of the American Society of Hematology 112 (4), 1329-1337, 2008 | 583 | 2008 |
| The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications K Podar, KC Anderson Blood 105 (4), 1383-1395, 2005 | 527 | 2005 |
| Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells T Hideshima, L Catley, H Yasui, K Ishitsuka, N Raje, C Mitsiades, K Podar, ... Blood 107 (10), 4053-4062, 2006 | 517 | 2006 |
| Critical role for Gab2 in transformation by BCR/ABL M Sattler, MG Mohi, YB Pride, LR Quinnan, NA Malouf, K Podar, ... Cancer cell 1 (5), 479-492, 2002 | 486 | 2002 |
| Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells T Hideshima, H Ikeda, D Chauhan, Y Okawa, N Raje, K Podar, ... Blood, The Journal of the American Society of Hematology 114 (5), 1046-1052, 2009 | 460 | 2009 |
| Bone marrow microenvironment and the identification of new targets for myeloma therapy K Podar, D Chauhan, KC Anderson Leukemia 23 (1), 10-24, 2009 | 423 | 2009 |
| Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application T Hayashi, T Hideshima, M Akiyama, K Podar, H Yasui, N Raje, S Kumar, ... British journal of haematology 128 (2), 192-203, 2005 | 388 | 2005 |
| Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells D Chauhan, G Li, R Shringarpure, K Podar, Y Ohtake, T Hideshima, ... Cancer research 63 (19), 6174-6177, 2003 | 317 | 2003 |
| Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation D Abraham, K Podar, M Pacher, M Kubicek, N Welzel, BA Hemmings, ... Journal of Biological Chemistry 275 (29), 22300-22304, 2000 | 313 | 2000 |
| Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target D Chauhan, AV Singh, M Brahmandam, R Carrasco, M Bandi, ... Cancer cell 16 (4), 309-323, 2009 | 308 | 2009 |
| A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase M Sattler, YB Pride, P Ma, JL Gramlich, SC Chu, LA Quinnan, S Shirazian, ... Cancer research 63 (17), 5462-5469, 2003 | 301 | 2003 |
| Role of B-cell–activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment YT Tai, XF Li, I Breitkreutz, W Song, P Neri, L Catley, K Podar, ... Cancer research 66 (13), 6675-6682, 2006 | 293 | 2006 |
| Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species JH Kim, SC Chu, JL Gramlich, YB Pride, E Babendreier, D Chauhan, ... Blood 105 (4), 1717-1723, 2005 | 287 | 2005 |
| A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma D Chauhan, M Velankar, M Brahmandam, T Hideshima, K Podar, ... Oncogene 26 (16), 2374-2380, 2007 | 280 | 2007 |
Giovanni TononSan Raffaele Scientific InstituteVerified email at hsr.it
